Table 2.
Correlation between clinicopathological patient characteristics and the expression of the insulin-like growth factor receptor 1 (IGF1R) in cancer cells in PDAC tissues.
| Total | Cytoplasmic IGF1R Expression | Membranous IGF1R Expression | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low HScore < 10 |
High HScore ≥ 10 |
Low HScore < 12 |
High HScore ≥ 12 |
||||||||
| n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | ||
| Gender | n p-Value (a) | 160 | 160 | 0.874 | 160 | 0.752 | |||||
| Male | 80 | (50.0) | 39 | (48.8) | 41 | (51.2) | 38 | (47.5) | 42 | (52.5) | |
| Female | 80 | (50.0) | 37 | (46.3) | 43 | (53.8) | 41 | (51.2) | 39 | (48.8) | |
| Age Group | n p-Value (a) | 160 | 160 | 1.000 | 160 | 1.000 | |||||
| <68.3 years | 80 | (50.0) | 38 | (47.5) | 42 | (52.5) | 39 | (48.8) | 41 | (51.2) | |
| ≥68.3 years | 80 | (50.0) | 38 | (47.5) | 42 | (52.5) | 40 | (50.0) | 40 | (50.0) | |
| T-Category | n p-Value (b) | 147 | 147 | 0.959 | 147 | 0.202 | |||||
| T1 | 4 | (2.7) | 3 | (75.0) | 1 | (25.0) | 2 | (50.0) | 2 | (50.0) | |
| T2 | 9 | (6.1) | 2 | (22.2) | 7 | (77.8) | 1 | (11.1) | 8 | (88.9) | |
| T3 | 130 | (88.4) | 65 | (50.0) | 65 | (50.0) | 70 | (53.8) | 60 | (46.2) | |
| T4a/b | 4 | (2.7) | 1 | (25.0) | 3 | (75.0) | 1 | (25.0) | 3 | (75.0) | |
| lymph node ratio | n p-Value (a) | 147 | 147 | 0.622 | 147 | 1.000 | |||||
| low (<0.133) | 73 | (49.7) | 37 | (50.7) | 36 | (49.3) | 37 | (50.7) | 36 | (49.3) | |
| high (≥0.133) | 74 | (50.3) | 34 | (45.9) | 40 | (54.1) | 37 | (50.0) | 37 | (50.0) | |
| N-Category | n p-Value (a) | 147 | 147 | 0.832 | 147 | 0.395 | |||||
| N0 | 27 | (18.4) | 14 | (51.9) | 13 | (48.1) | 16 | (59.3) | 11 | (40.7) | |
| N+ (N1, N2) | 120 | (81.6) | 57 | (47.5) | 63 | (52.5) | 58 | (48.3) | 62 | (51.7) | |
| M-Category | n p-Value (a) | 135 | 135 | 0.590 | 135 | 0.419 | |||||
| M0 | 120 | (88.9) | 59 | (49.2) | 61 | (50.8) | 63 | (52.5) | 57 | (47.5) | |
| M1 | 15 | (11.1) | 6 | (40.0) | 9 | (60.0) | 6 | (40.0) | 9 | (60.0) | |
| UICC Stage | n p-Value (b) | 129 | 129 | 0.647 | 129 | 0.175 | |||||
| IA | 3 | (2.3) | 2 | (66.7) | 1 | (33.3) | 2 | (66.7) | 1 | (33.3) | |
| IB | 2 | (1.6) | 0 | (0.0) | 2 | (100.0) | 0 | (0.0) | 2 | (100.0) | |
| IIA | 14 | (10.9) | 7 | (50.0) | 7 | (50.0) | 10 | (71.4) | 4 | (28.6) | |
| IIB | 92 | (71.3) | 46 | (50.0) | 46 | (50.0) | 47 | (51.1) | 45 | (48.9) | |
| III | 3 | (2.3) | 1 | (33.3) | 2 | (66.7) | 1 | (33.3) | 2 | (66.7) | |
| IV | 15 | (11.6) | 6 | (40.0) | 9 | (60.0) | 6 | (40.0) | 9 | (60.0) | |
| L-Category | n p-Value (a) | 145 | 145 | 0.068 | 145 | 0.741 | |||||
| L0 | 73 | (50.3) | 41 | (56.2) | 32 | (43.8) | 38 | (52.1) | 35 | (47.9) | |
| L1 | 72 | (49.7) | 29 | (40.3) | 43 | (59.7) | 35 | (48.6) | 37 | (51.4) | |
| V-Category | n p-Value (a) | 144 | 144 | 0.434 | 144 | 0.845 | |||||
| V0 | 110 | (76.4) | 55 | (50.0) | 55 | (50.0) | 56 | (50.9) | 54 | (49.1) | |
| V1 | 34 | (23.6) | 14 | (41.2) | 20 | (58.8) | 16 | (47.1) | 18 | (52.9) | |
| Pn-Category | n p-Value (a) | 124 | 124 | 1.000 | 124 | 1.000 | |||||
| Pn0 | 12 | (9.7) | 7 | (58.3) | 5 | (41.7) | 7 | (58.3) | 5 | (41.7) | |
| Pn1 | 112 | (90.3) | 60 | (53.6) | 52 | (46.4) | 60 | (53.6) | 52 | (46.4) | |
| Grading | n p-Value (a) | 153 | 154 | 0.277 | 154 | 0.327 | |||||
| G1 | 8 | (5.2) | 6 | (75.0) | 2 | (25.0) | 6 | (75.0) | 2 | (25.0) | |
| G2 | 78 | (51.0) | 35 | (45.6) | 43 | (54.4) | 39 | (50.0) | 39 | (50.0) | |
| G3 | 67 | (43.8) | 32 | (47.8) | 35 | (52.2) | 31 | (46.3) | 36 | (53.7) | |
| R-Status | n p-Value (a) | 141 | 141 | 0.160 | 141 | 0.547 | |||||
| R0 | 108 | (76.6) | 48 | (44.4) | 60 | (55.6) | 53 | (49.1) | 55 | (50.9) | |
| R1 | 32 | (22.7) | 19 | (59.4) | 13 | (40.6) | 18 | (56.3) | 14 | (43.8) | |
| R2 | 1 | (0.7) | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 1 | (100.0) | |
| Diabetes status | n p-Wert (a) | 101 | 101 | 0.277 | 101 | 0.622 | |||||
| no diabetes | 73 | (72.3) | 34 | (46.6) | 39 | (53.4) | 33 | (45.2) | 40 | (54.8) | |
| type 2 diabetes | 23 | (22.8) | 15 | (65.2) | 8 | (34.8) | 13 | (56.5) | 10 | (43.5) | |
| postoperative diabetes | 5 | (5.0) | 2 | (40.0) | 3 | (60.0) | 3 | (60.0) | 2 | (40.0) | |
| Overall Survival [Months] | p-Value (c) | 155 | 0.671 | 155 | 0.194 | ||||||
| Total/Events/Censored | 155/107/48 | 74/52/22 | 81/55/26 | 75/51/24 | 80/56/24 | ||||||
| Median Survival | 14.9 ± 1.9 | 15.7 ± 2.1 | 14.7 ± 3.5 | 15.7 ± 2.6 | 13.5 ± 2.0 | ||||||
| 95% C.I. | 11.1–18.6 | 11.7–19.7 | 7.9–21.4 | 10.5–20.8 | 9.6–17.4 | ||||||
| Tumor Specific Survival [Months] | p-Value (c) | 153 | 0.832 | 153 | 0.367 | ||||||
| Total/Events/Censored | 153/100/53 | 73/49/24 | 80/51/29 | 74/49/25 | 79/51/28 | ||||||
| Median Survival | 15.7 ± 1.9 | 15.7 ± 2.0 | 15.0 ± 3.0 | 15.7 ± 2.6 | 14.9 ± 2.8 | ||||||
| 95% C.I. | 11.9–19.4 | 11.8–19.6 | 9.0–21.0 | 10.6–20.7 | 9.4–20.4 | ||||||
(a) Fisher’s exact test, (b) Kendall’s tau test, (c) Log-rank test.